Palifermin, a recombinant human form of keratinocyte growth factor (KGF), is the only U.S. Food & Drug Administration–approved agent that is used to prevent oral mucositis in patients with bone marrow transplantation, but fibroblast growth factor receptor 2b (FGFR2b) is often overexpressed in cancer cells and increases the risk of tumor growth (6). Here, FGF7 is linked to neoplasm.